Clinical Trial

Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma（AICRC）

Study acronym: AICRC
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can improve patients' recurrence-free survival. The primary study endpoint of this prospective study is the 2-year recurrence-free survival.
Trial Details
NCT Number NCT06997913
Lead Sponsor Hengchao Yu
Conditions Lymph Node Metastasis, Neurovascular Invasion, Pathology Showed R1 Resection
Enrollment 10 participants
Start Date 2025-03-15
Primary Completion 2026-05-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-31